Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
X4 Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
XFOR
Nasdaq
8731
https://www.x4pharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for X4 Pharmaceuticals Inc
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- May 1st, 2024 8:05 pm
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
- Apr 30th, 2024 12:00 pm
XFOR: XOLREMDI™ Approved by FDA…
- Apr 30th, 2024 10:20 am
UPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease
- Apr 29th, 2024 10:47 am
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
- Apr 29th, 2024 10:30 am
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns
- Apr 11th, 2024 2:15 pm
XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…
- Apr 2nd, 2024 10:16 am
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
- Apr 1st, 2024 12:00 pm
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call Transcript
- Mar 22nd, 2024 4:47 pm
Q4 2023 X4 Pharmaceuticals Inc Earnings Call
- Mar 22nd, 2024 2:09 am
X4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial Results
- Mar 21st, 2024 1:11 pm
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
- Mar 21st, 2024 10:01 am
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
- Mar 12th, 2024 12:00 pm
XFOR: Update on Phase 2 CN Trial at ASH 2023
- Dec 15th, 2023 11:00 am
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
- Dec 9th, 2023 5:00 pm
XFOR: Mavorixafor NDA Accepted by FDA; PDUFA Date of April 30, 2024
- Nov 13th, 2023 11:00 am
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2023 Earnings Call Transcript
- Nov 10th, 2023 8:46 pm
X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences
- Nov 10th, 2023 1:00 pm
Q3 2023 X4 Pharmaceuticals Inc Earnings Call
- Nov 10th, 2023 6:48 am
X4 Pharmaceuticals Inc (XFOR) Reports Q3 2023 Financial Results and Corporate Progress
- Nov 9th, 2023 2:29 pm
Scroll